Patient description: The patient is a 3-day-old female infant with jaundice that started one day ago. She was born at 34w of gestation and kept in an incubator due to her gestational age. Vital signs were reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 2.1 kg, length is 45 cm, and head circumference 32 cm. She presents with yellow sclera and icteric body. Her liver and spleen are normal to palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anxiety Stress, Psychological Male and female participants aged 18-70 years 2. Females of childbearing potential must use reliable contraception during the study period; acceptable methods of birth control all hormonal methods, IUDs, complete abstinence, effective physical barriers (e.g. condoms), or confirmed vasectomy of partner (if that information is volunteered by the participant) 3. Participants must be in good health status based on medical history and physical examination, including vital signs and clinical laboratory tests 4. Participants must refrain from taking any prescription or over the counter medication within the 14 days prior to the beginning of the study and during the study period 5. Participants must be non-smokers or light/occasional smokers (not more than 10 cigarettes per day) 6. Alcohol consumption should not exceed 3 drinks on any single day and no more than 7 drinks per week in women and no more than 4 drinks on any single day and no more than 14 drinks per week for men 7. BMI of 18.5-30 kg/m2 excluding markedly underweight and obese individuals 8. Participants must be willing to give written informed consent after the nature of the study has been fully explained  Participants demonstrating uncontrolled clinically significant physical disease or abnormal laboratory test results within 14 days prior to the start of the study 2. Participants with current or history of alcohol or drug use disorder 3. Participants with any history of significant drug super-sensitivity, anaphylaxis, or anaphylactic reaction 4. Participants taking prescription medication or OTC medication within 14 days prior to 5. Participants who have a history of any significant psychiatric disorder or currently significant psychiatric symptoms 6. Participants with a family history of serious mental illness in first-degree relatives 7. Participants in a situation or having any condition which, in the opinion of the investigator, may interfere with optimal participation in the study 8. Participants testing positive for amphetamine, cannabinoids, cocaine, barbiturates, benzodiazepines, opioids or hallucinogens 9. Use of other non-prescription natural health products with known anti-anxiety effects 10. Known allergy to any of the medicinal and non-medicinal ingredients in any conditions of the study